CCKBR: Gastrin/cholecystokinin type B receptor
Receptor for the peptide hormones gastrin and cholecystokinin (CCK).
- Drugs that act on it: 3
- Approved: 0
- In phases 1 to 3: 3
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on CCKBR, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 2
- Protein or peptide 1
| Itriglumide | Phase 2 | — | Small molecule | Antagonist | 0 |
| Netazepide | Phase 2 | Trio Medicines Ltd. | Protein or peptide | Antagonist | 0 |
| CI-988 | Phase 1 | — | Small molecule | Antagonist | 0 |
- Peptic ulcer disease0.46
- Gastroesophageal reflux disease0.44
- Hypercholesterolemia, familial, 10.33
- Duodenal ulcer0.32
- Esophageal disorder0.28
- Mathematical ability0.15
- Duodenal disorder0.13
- Stomach disorder0.13
- Neoplasm0.11
- Barrett esophagus0.10
- Pancreatic neoplasm0.10
- Chronic atrophic gastritis0.10
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL298, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P32239, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets